Abstract 461P
Background
POLARIS is a prospective, observational real-world study of pts with HR+/HER2− ABC receiving palbociclib in routine clinical practice. As part of this study, we evaluated the impact of comorbidities on pt quality of life (QoL) using the EORTC-QLQ-C30 questionnaire.
Methods
EORTC data were collected at baseline, monthly for the first 3 months, and every 3 months thereafter until palbociclib discontinuation; here we report absolute global QoL and functional/symptom subscales scores according to pt baseline Charlson comorbidity index (CCI) score (grouped 0, 1–2, and 3+) at study baseline, month 6, 12 and 18. EORTC differences of ≥10 between CCI groups at each timepoint and within a CCI group over time were considered clinically meaningful. Differences in global QoL/subscale scores between CCI groups at each timepoint were compared using a two-sample t-test.
Results
Between January 2017 and December 2018, 1285 pts were enrolled, and 1250 received ≥1 dose of palbociclib. At baseline, pts had a median of 2 (range 0–9) comorbidities. 30.2%, 54.6% and 15.3% of pts had a CCI score 0, 1–2, and 3+, respectively. The most frequent comorbidities were vascular (54.3%), psychiatric (26.6%), blood/lymphatic system (18.4%), and metabolic/nutritional (18.2%) disorders. Generally, absolute mean global QoL and functional/symptom subscale scores (range: 0 to 100) were preserved from baseline to Month 18 within each CCI group (Table). Overall, differences in mean global QoL scores (and functional/symptom subscale scores) between the CCI 0 and CCI 1‒2 were similar at each timepoint; while notably lower scores (less favorable) were observed for the smaller CCI 3+ group. Table: 461P
Global QoL in pts with HR+/HER2– ABC by CCI
Absolute mean* | Time point | CCI score | ||||
0 | 1‒2 | 3+ | ||||
Baseline | 69.89 (n=336) | 62.95 (n=651) | 56.90 (n=180) | |||
Month 6 | 73.29 (n=219) | 69.69 (n=400) | 60.40 (n=113) | |||
Month 12 | 74.23 (n=151) | 70.42 (n=262) | 59.98 (n=71) | |||
Month 18 | 75.08 (n=103) | 69.28 (n=198) | 62.02 (n=52) | |||
Diff in means | CCI 0 vs 1-2 | CCI 0 vs 3+ | CCI 1-2 vs 3+ | |||
Diff | p-value | Diff | p-value | Diff | p-value | |
Baseline | 6.94 | <0.0001 | 12.99 | <0.0001 | 6.06 | 0.0028 |
Month 6 | 3.60 | 0.0401 | 12.89 | <0.0001 | 9.29 | <0.0001 |
Month 12 | 3.81 | 0.0546 | 14.25 | <0.0001 | 10.44 | 0.0002 |
Month 18 | 5.80 | 0.0225 | 13.06 | 0.0004 | 7.26 | 0.0314 |
*Higher scores more favorable. Subscales were consistent with global QoL. Data cut off January 2023. CCI, Charlson comorbidity index; Diff, difference; QoL, quality of life.
Conclusions
QoL of pts with HR+/HER2- ABC treated with palbociclib differed by comorbidity level, with a general preservation in their relationship over 18 months.
Clinical trial identification
NCT03280303.
Editorial acknowledgement
Medical writing support, conducted in accordance with Good Publication Practice (GPP3) and the International Committee of Medical Journal Editors (ICMJE) guidelines, was provided by Sophie Wicken and Martin Dalziel, PhD of Oxford PharmaGenesis, Inc., Newtown, PA, with funding provided by Pfizer Inc., USA.
Legal entity responsible for the study
Pfizer Inc., USA.
Funding
This work was supported by Pfizer Inc., USA.
Disclosure
J.L. Blum: Financial Interests, Personal, Other, Paid consultant: Puma Biotechnology, Athenix, Inc., OncLive, Biotheranostics, AstraZeneca, Immunomedics, Inc.; Other, Personal, Other, Research to Practice: Sanofi, Pfizer Inc., Tempus, TD2; Other, Personal, Other, Speaker's Bureau: Pfizer, Tempus. G. Rocque: Financial Interests, Institutional, Funding, Research funding: Genentech, Pfizer, and Carevive ; Financial Interests, Personal, Other, Consulting fees: Pfizer, Gilead, and Flatiron. Y. Ji: Financial Interests, Personal, Advisory Board: Janssen, AstraZeneca and BeiGene. J. Migas: Financial Interests, Institutional, Other, Contracted research (clinical trials): Pfizer, Inc., AstraZeneca, Jazz Pharmaceuticals. E. Jepsen: Financial Interests, Personal, Other, Employee: Novant Health Cancer Institute. E. Gauthier: Financial Interests, Full or part-time Employment: Pfizer Inc.; Financial Interests, Stocks/Shares: Pfizer Inc. Y. Wang: Financial Interests, Full or part-time Employment: Pfizer Inc.; Financial Interests, Stocks/Shares: Pfizer Inc. M.Z. Montelongo, C. Chen: Financial Interests, Personal, Full or part-time Employment: ICON; Financial Interests, Institutional, Funding: Pfizer Inc. J. Cappelleri: Financial Interests, Full or part-time Employment: Pfizer Inc.; Financial Interests, Stocks/Shares: Pfizer Inc. . D. Tripathy: Financial Interests, Institutional, Research Funding: Novartis, Pfizer, Polyphor; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, OncoPep, GSK, Gilead, Personalis, Sermonix, Pfizer, Novartis, Puma Biotechnology, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1277P - HRD status of patients with early stage non-small cell lung cancer
Presenter: Apostolos Klinakis
Session: Poster session 04
1278P - ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
Presenter: Ernest Nadal
Session: Poster session 04
1279P - Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
Presenter: Edgar Amorin
Session: Poster session 04
1280P - Comprehensive characterization of human lung squamous cell carcinoma identifies high TFRC expression as a mark of poorly immunogenic tumours
Presenter: María Gutiérrez Pérez
Session: Poster session 04
1281P - Effect of Fra-2 expression on tumour immunogenicity and prognosis in KRAS-mutant lung adenocarcinoma
Presenter: Alvaro Ucero
Session: Poster session 04
1282P - Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Yoshitaka Zenke
Session: Poster session 04
1283P - Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
Presenter: Daniel Hughes
Session: Poster session 04
1284P - Lung cancer among patients with chronic obstructive pulmonary disease: A Danish 10-year observational study of the overlapping population
Presenter: Margrethe Henriksen
Session: Poster session 04
1285P - Lung cancer in never smokers (LCINS): Clinicopathological characteristics and treatment outcomes from a university cancer centre in London
Presenter: Charalampos Gousis
Session: Poster session 04
1287P - Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
Presenter: Bharathi Muthusamy
Session: Poster session 04